Cardiotoxicity of imatinib mesylate: An extremely rare phenomenon or a major side effect? [2]

Annals of the Rheumatic Diseases

Volumn 66, Issue 6, 2007, Pages 836-

  Distler, Jörg H W ^a   Distler, Oliver ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG INHIBITION; GASTROINTESTINAL TUMOR; HUMAN; LETTER; LEUKEMIA; PHENOMENOLOGY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS;

ANTINEOPLASTIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 34249822217     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.067710     Document Type: Letter

References (8)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
2. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safely of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Elisabeth Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
4. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-3.
5. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116:2633-42.
6. Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate decreases the production of extracellular matrix and prevents the development of experimental dermal fibrosis. Arthritis Rheum 2006;56:311-22.
7. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16.
8. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.